Over 50% of the top 20 global innovative pharma companies saw a decrease in their market cap (MCap) in the first quarter (Q1) of 2020, while nearly all of these pharma companies saw an increase in their MCap over 2019 (Q1 to Q4 2019), witnessing an overall 7.9% decrease in MCap over Q1 2020 equivalent to $2.2 trillion.

The reversal of fortune of the companies on this list due to Covid-19 may seem dramatic due to their long-term growth. Read more here.